Ignite Creation Date:
2024-05-06 @ 10:35 AM
Last Modification Date:
2024-10-26 @ 12:32 PM
Study NCT ID:
NCT03293407
Status:
COMPLETED
Last Update Posted:
2021-05-26
First Post:
2017-09-20
Brief Title:
Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Ventavis Iloprost Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VENTASTEP
Brief Summary:
The main aim of the observational VENTASTEP study was to investigate the association between changes in clinical outcome measures and changes in device outcome measures in PAH patients using the new Breelib nebulizer in a real life setting
The study was not designed to investigate or confirm the effectiveness and safety of iloprost
The study was not designed to investigate or confirm the effectiveness and safety of iloprost
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None